<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is caused by mutations in the fibrillin-1 gene and dysregulation of transforming growth factor-beta (TGF-beta) </plain></SENT>
<SENT sid="1" pm="."><plain>Recent evidence suggests that <z:chebi fb="0" ids="6541">losartan</z:chebi>, an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 blocker that blunts TGF-beta activation, may be an effective treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that dysregulation of TGF-beta might be mirrored in circulating TGF-beta concentrations </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Serum obtained from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> mutant mice (Fbn1(C1039G/+)) treated with <z:chebi fb="0" ids="6541">losartan</z:chebi> was analyzed for circulating TGF-beta1 concentrations and compared with those from placebo-treated and <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="4" pm="."><plain>Aortic root size was measured by echocardiography </plain></SENT>
<SENT sid="5" pm="."><plain>Data were validated in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and healthy individuals </plain></SENT>
<SENT sid="6" pm="."><plain>In mice, circulating total TGF-beta1 concentrations increased with age and were elevated in older untreated Fbn1(C1039G/+) mice compared with <z:mp ids='MP_0002169'>wild-type</z:mp> mice (P=0.01; n=16; mean+/-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, 115+/-8 ng/mL versus n=17; mean+/-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, 92+/-4 ng/mL) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi>-treated Fbn1(C1039G/+) mice had lower total TGF-beta1 concentrations compared with age-matched Fbn1(C1039G/+) mice treated with placebo (P=0.01; n=18; 90+/-5 ng/mL), and circulating total TGF-beta1 levels were indistinguishable from those of age-matched <z:mp ids='MP_0002169'>wild-type</z:mp> mice (P=0.8) </plain></SENT>
<SENT sid="8" pm="."><plain>Correlation was observed between circulating TGF-beta1 levels and aortic root diameters in Fbn1(C1039G/+) and <z:mp ids='MP_0002169'>wild-type</z:mp> mice (P=0.002) </plain></SENT>
<SENT sid="9" pm="."><plain>In humans, circulating total TGF-beta1 concentrations were elevated in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> compared with control individuals (P&lt;0.0001; n=53; 15+/-1.7 ng/mL versus n=74; 2.5+/-0.4 ng/mL) </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> patients treated with <z:chebi fb="0" ids="6541">losartan</z:chebi> (n=55) or beta-blocker (n=80) showed significantly lower total TGF-beta1 concentrations compared with untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> patients (P&lt; or =0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Circulating TGF-beta1 concentrations are elevated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and decrease after administration of <z:chebi fb="0" ids="6541">losartan</z:chebi>, beta-blocker therapy, or both and therefore might serve as a prognostic and therapeutic marker in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
</text></document>